Related references
Note: Only part of the references are listed.Immune checkpoint inhibitor-related myocarditis
Kazuko Tajiri et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2018)
Fatal Myocarditis Following Treatment with the PD-1 Inhibitor Nivolumab
Daniel R. Matson et al.
JOURNAL OF FORENSIC SCIENCES (2018)
Immune checkpoint molecules in acute myeloid leukaemia: managing the double-edged sword
Willemijn Hobo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition
Nina Deppisch et al.
ONCOTARGET (2017)
Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status
Ibrahim Aldoss et al.
HAEMATOLOGICA (2017)
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
Jarushka Naidoo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Recent developments in immunotherapy of acute myeloid leukemia
Felix S. Lichtenegger et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Measurable residual disease testing in acute myeloid leukaemia
C. S. Hourigan et al.
LEUKEMIA (2017)
Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
Cristina Ilcus et al.
ONCOTARGETS AND THERAPY (2017)
Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status
Ibrahim Aldoss et al.
HAEMATOLOGICA (2017)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab et al.
FRONTIERS IN PHARMACOLOGY (2017)
The combination of checkpoint immunotherapy and targeted therapy in cancer
Niki Karachaliou et al.
ANNALS OF TRANSLATIONAL MEDICINE (2017)
Phase IB/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML.
Naval Guastad Daver et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia
Hanna A. Knaus et al.
CURRENT DRUG TARGETS (2017)
CAR T-cells merge into the fast lane of cancer care
Noelle V. Frey et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
C. Krupka et al.
LEUKEMIA (2016)
Toxicities of Immunotherapy for the Practitioner
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Scott N. Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
Thomas Koehnke et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy
Sebastian Kobold et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Immunotherapy for Acute Myeloid Leukemia
Felix S. Lichtenegger et al.
SEMINARS IN HEMATOLOGY (2015)
T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330
G. S. Laszlo et al.
BLOOD CANCER JOURNAL (2015)
Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy
Sebastian Kobold et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia
J. Loke et al.
ANNALS OF HEMATOLOGY (2015)
Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia
N. Sandhoefer et al.
LEUKEMIA (2015)
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330
Christina Krupka et al.
BLOOD (2014)
Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML
George S. Laszlo et al.
BLOOD (2014)
The past and future of CD33 as therapeutic target in acute myeloid leukemia
George S. Laszlo et al.
BLOOD REVIEWS (2014)
Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment
Holger Kroenig et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell-Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia
Matthias Friedrich et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
A. Ehninger et al.
BLOOD CANCER JOURNAL (2014)
T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cell
Claudia C. Roskopf et al.
ONCOTARGET (2014)
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
David T. Teachey et al.
BLOOD (2013)
Current strategies in immunotherapy for acute myeloid leukemia
Felix S. Lichtenegger et al.
IMMUNOTHERAPY (2013)
Structure and Interactions of the Human Programmed Cell Death 1 Receptor
Xiaoxiao Cheng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct
M. Aigner et al.
LEUKEMIA (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Optimization of protein purification and characterization using Thermofluor screens
Stephane Boivin et al.
PROTEIN EXPRESSION AND PURIFICATION (2013)
Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease
Jean-Claude Chomel et al.
BLOOD (2011)
Integrative phospho-proteomic and genomic analyses identify AXL as a potential biomarker and therapeutic target for NRAS-mutated melanoma
Inna V. Fedorenko et al.
CANCER RESEARCH (2011)
An evidence for adhesion-mediated acquisition of acute myeloid leukemic stem cell-like immaturities
Keiji Funayama et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors
Celine Berthon et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical Outcome
Annika Dufour et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Monoclonal antibody-induced cytokine-release syndrome
Peter J. Bugelski et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2009)
Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components
Evren Alici et al.
BLOOD (2008)
Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia
Tobias Benthaus et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Endotoxin limits in formulations for preclinical research
Padma Malyala et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2008)
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
David Yin-Wei Lin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class
Klaus Brischwein et al.
JOURNAL OF IMMUNOTHERAPY (2007)
High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group
A-L Taksin et al.
LEUKEMIA (2007)
MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors
K Brischwein et al.
MOLECULAR IMMUNOLOGY (2006)
Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia
DC Taussig et al.
BLOOD (2005)
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence
RA Larson et al.
CANCER (2005)
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct
P Hoffmann et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Ex vivo expansion of human hematopoietic stem cells by direct delivery of the HOXB4 homeoprotein
S Amsellem et al.
NATURE MEDICINE (2003)
Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody
T Dreier et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Share Paper
